Trial Profile
Phase I/II Study of Ustekinumab in Patients With New-onset Type 1 Diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms UST1D
- 24 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
- 24 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.
- 24 May 2016 Status changed from recruiting to active, no longer recruiting.